Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CAMP4 Therapeutics Corporation ( (CAMP) ) has shared an announcement.
On June 11, 2025, CAMP4 Therapeutics Corporation held its annual meeting of stockholders, where key decisions were made. The meeting resulted in the election of Class I directors to serve until 2028 and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (CAMP) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on CAMP4 Therapeutics Corporation stock, see the CAMP Stock Forecast page.
More about CAMP4 Therapeutics Corporation
CAMP4 Therapeutics Corporation operates in the biotechnology industry, focusing on developing therapies that regulate gene expression to treat diseases.
Average Trading Volume: 287,090
Technical Sentiment Signal: Strong Sell
Current Market Cap: $33.27M
Find detailed analytics on CAMP stock on TipRanks’ Stock Analysis page.